APC Conjugated Human PD1 Protein (C-Fc)

Cat # Size Price Quantity
80330325 ug$245
803304100 ug$595

Product Details


ApplicationFC
FormatLiquid, APC
Expression HostHEK293
Target NamePD1, PDCD1, CD279, SLEB2
SpeciesHuman
SourcesHuman PD-1 protein (NP_005009.2) (Leu25-Gln167) with C-terminus Fc tag is expressed in HEK293 cells and conjugated to APC
accession numberQ15116
Molecular WeightThe protein has a predicted molecular weight of 19 kDa. Under DTT-reducing conditions, it migrates at approximately 25-30 kDa on SDS-PAGE prior to conjugation.
Affinity TagC-Fc
Formulation1xPBS buffer, pH7.4, 0.09% NaN3 with a carrier protein
Endotoxin levelNot tested
Protein Concentration25µg size is bottled at 0.1mg/mL concentration. 100 µg size is bottled at lot specific concentration.
Storage and HandlingBriefly centrifuge the vial upon receipt. An unopened vial may be stored at 2–8°C for up to six months.

Background Information


Programmed Death-1 receptor (PD-1, also known as CD279) is a type I transmembrane protein and an immunoregulatory receptor of the CD28/CTLA-4 family. It is expressed on activated T cells, B cells, monocytes, dendritic cells, and some thymocytes. PD-1 binds to ligands PD-L1 and PD-L2, transmitting co-inhibitory signals that suppress T-cell activation, proliferation, cytokine production, and cytotoxic activity by dephosphorylating key signaling molecules. This mechanism promotes immune tolerance and prevents autoimmunity but is exploited by tumors to evade immune surveillance, as many tumors upregulate PD-L1. When tumor-expressed PD-L1 engages PD-1 on immune cells, it blocks T-cell activation and promotes immune exhaustion. Monoclonal antibodies targeting the PD-1/PD-L1 pathway have revolutionized cancer therapy by releasing this immune brake, enhancing anti-tumor immunity and leading to tumor regression in many cancers. Examples include nivolumab and pembrolizumab. This immunotherapy approach is now a major focus in oncology, offering a powerful tool to boost the immune system against cancer and reshape treatment paradigms.